Contributions
Abstract: P747
Type: Poster
Abstract Category: Therapy - disease modifying - Treatment of progressive MS
Background: Biotin is vitamin acting as a coenzyme for carboxylases involved in key steps of energy metabolism and fatty acids synthesis and could promote remyelination. One double blind placebo controlled trial showed improvement in a significant proportion of patients with progressive multiple sclerosis (MS). Biotin is available in France in temporary use since July 2015.
Objective: To study baseline characteristics and follow up of patients treated with Biotin in Dijon (Burgundy).
Method: We studied all progressive MS treated with biotin included in EDMUS database. EDMUS is used in Dijon since 2000 and includes patients from burgundy MS center. We calculated number of primary progressive (PP) or secondary progressive (SP) form of MS, mean age and EDSS at biotin initiation, proportion of patients for which biotin was used as add on therapy, number of adverse events mean, Clinical Global Impression (CGI) Scale assessed by patient..
Results: 50 patients were treated with biotin, 38 (63% women) had SPMS and 12 (42% women) PPMS. The mean age at MS onset was 30.18 and 42.83 years respectively. Mean age at biotin initiation was 54.79 years with mean EDSS at 7.0 for SPMS; 59.5 years and 6.5 for PPMS. The mean duration of treatment was 57 days. 13 patients had biotin as add on therapy among SPMS
(11 immunosupressor 2 immunomodulator) and 1 for PPMS (1 immunosuppressor). Four patients with SPMS reported adverse events (skin rash, hyperpilosity, diarrhea, false hyperthyroidism) and
1 patient with PPMS (constipation). No neurological worsening was noticed for all patients with mean CGI at 4.
Conclusions: Biotin is well tolerated. The false hyperthyroidism corresponds to biological abnormality due to biotin-streptavidin based hormonal dosage.
Disclosure: The authors have nothing to disclose
Abstract: P747
Type: Poster
Abstract Category: Therapy - disease modifying - Treatment of progressive MS
Background: Biotin is vitamin acting as a coenzyme for carboxylases involved in key steps of energy metabolism and fatty acids synthesis and could promote remyelination. One double blind placebo controlled trial showed improvement in a significant proportion of patients with progressive multiple sclerosis (MS). Biotin is available in France in temporary use since July 2015.
Objective: To study baseline characteristics and follow up of patients treated with Biotin in Dijon (Burgundy).
Method: We studied all progressive MS treated with biotin included in EDMUS database. EDMUS is used in Dijon since 2000 and includes patients from burgundy MS center. We calculated number of primary progressive (PP) or secondary progressive (SP) form of MS, mean age and EDSS at biotin initiation, proportion of patients for which biotin was used as add on therapy, number of adverse events mean, Clinical Global Impression (CGI) Scale assessed by patient..
Results: 50 patients were treated with biotin, 38 (63% women) had SPMS and 12 (42% women) PPMS. The mean age at MS onset was 30.18 and 42.83 years respectively. Mean age at biotin initiation was 54.79 years with mean EDSS at 7.0 for SPMS; 59.5 years and 6.5 for PPMS. The mean duration of treatment was 57 days. 13 patients had biotin as add on therapy among SPMS
(11 immunosupressor 2 immunomodulator) and 1 for PPMS (1 immunosuppressor). Four patients with SPMS reported adverse events (skin rash, hyperpilosity, diarrhea, false hyperthyroidism) and
1 patient with PPMS (constipation). No neurological worsening was noticed for all patients with mean CGI at 4.
Conclusions: Biotin is well tolerated. The false hyperthyroidism corresponds to biological abnormality due to biotin-streptavidin based hormonal dosage.
Disclosure: The authors have nothing to disclose